These results provide evidence: (a) that Notch inhibitor might have therapeutic benefits via enhancing efficacy of sorafenib for HCC patients; and (b) that GSI and sorafenib, in targeting the Notch1-Snail1 pathway, provides a potential molecular mechanism. The gene discussed is NOTCH1; the disease is hepatocellular carcinoma.